following an abbreviated submission
aprepitant (Emend®) is accepted for use within NHS Scotland.
Indication under review: As part of combination therapy, for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy in children, toddlers and infants from the age of six months to <12 years (powder for oral suspension) and adolescents from the age of 12 years to 17 years (hard capsules).
SMC has previously accepted aprepitant for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based chemotherapy in adults. The marketing authorisation has since been extended to cover prevention of nausea and vomiting in adults associated with highly emetogenic non-cisplatin based chemotherapy. SMC does not plan to assess this minor licence extension.
Download detailed advice69KB (PDF)
Medicine details
- Medicine name:
- aprepitant (Emend)
- SMC ID:
- 1252/17
- Indication:
- As part of combination therapy, for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy in children, toddlers and infants from the age of six months to <12 years (powder for oral suspension) and adolescents from the age of 12 years to 17 years (hard capsules).
- Pharmaceutical company
- MSD
- BNF chapter
- Central nervous system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 July 2017